Latest Conference Content

There is no question that posttraumatic headache and migraines are related, said the head of neurology research at the Mayo Clinic’s Arizona campus; the unknown issue is to what extent they are related.

The entry of a new class of migraine therapies has created a new wave of excitement. A presentation at the Migraine Trust International Symposium reviewed what clinicians now know about calcitonin gene-related peptide (CGRP) blockers.

At a session Tuesday at the Migraine Trust International Symposium, one presentation delved into findings published this year in medication overuse headaches, prevention, and pathophysiology of migraine as well as cluster headaches.

Two neurologists discuss what is known and unknown in switching patients with migraine from one calcitonin gene-related peptide (CGRP) inhibitor to another.

In an open-label extension spanning 5 years, the safety profile of erenumab was consistent with the double-blind treatment phase of the study, and there were no increases in adverse event rates.

Speakers at Patient-Centered Oncology Care® highlighted injustices in the US health care system, the risk of financial toxicity, and how providers can do a better job to ensure their patients achieve health equity, during a panel discussion.

CMMI's Alexandra Chong, PhD, discusses COVID-19 related flexibilities under the Oncology Care Model, and a panel discusses its successor.

A gradual acceptance among physicians has been observed in adopting quality care initiatives that provide cost-saving, improved patient experience in cancer care, noted Kerin Adelson, MD, of Smilow Cancer Hospital at Yale New Haven/Yale Cancer Center.

Kassandra Munger, ScD, of the Harvard TH Chan School of Public Health, discusses findings that vitamin D deficiencies are linked to a greater risk of multiple sclerosis.

The biggest difference between ocrelizumab and the recently approved ofatumumab is that ofatumumab can be taken at home for relapsing forms of multiple sclerosis (MS), explained Patricia K. Coyle, MD.

Researchers hope that a more targeted retinoid acid X receptor compound could repair myelin without the adverse effects seen in every patient in this trial, which tested an already approved cancer drug.

Testing for coronavirus disease 2019 (COVID-19) before procedures has become a fixture of City of Hope's efforts to protect patients with cancer and staff, noted Harlan Levine, MD, president of Strategy and Business Ventures at City of Hope.

Aligned with ASCO's Patient-Centered Oncology Payment model, Anthem has launched its value-based strategy called the oncology medical home, which seeks to promote quality metrics and improve outcome measures in cancer care.

Disease-modifying therapies (DMTs) are primarily effective through immunomodulation, in that they target relapse prevention, said Burcu Zeydan, MD, assistant professor of neurology, assistant professor of radiology, at Mayo Clinic.

Progress within the adoption of clinical pathways, particularly in achieving standardization in cancer care, will be further discussed at Patient-Centered Oncology Care 2020®.

The uncertainties precipitated by the coronavirus disease 2019 (COVID-19) pandemic around cancer care delivery are a challenging topic to be further addressed at this year’s Patient-Centered Oncology Care® 2020 virtual meeting.

Through this year's virtual format for Patient-Centered Oncology Care® 2020, participants will be able to attend sessions, ask questions, and gain insight in an immediate, efficient way.

The opportunity that precision medicine presents in the field of oncology will be further discussed during this year’s Patient-Centered Oncology Care® 2020 virtual meeting.

As cancer care providers, aligning care with each patient's personal goals is a key point to be further discussed at this year's Patient-Centered Oncology Care® 2020 virtual conference.

For this year's Patient-Centered Oncology Care® 2020 virtual conference, the discussion on clinical pathways will address how to optimize new data on innovations within oncology.

At this year's Patient-Centered Oncology Care® 2020 virtual conference, purported lack of incentives, transparency in the supply chain of pharmacy benefit manager (PBM) operations, and the overall health care system will be discussed.

During a featured discussion at this year’s Patient-Centered Oncology Care® 2020 virtual meeting, innovations and subsequent challenges in employing these advances within the treatment of cancer will be addressed.

Obesity is common in the general population and research has shown it can increase the risk of multiple sclerosis (MS), as well as increase diagnostic delays, explained Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba.

Nurses often get involved with patients with multiple sclerosis (MS) before their diagnosis and then work to educate them on the disease and its care, said Amy Perrin Ross, APN, MSN, CNRN, MSCN, Neuroscience Program Coordinator at Loyola University Medical Center.

To the extent that some factors are modifiable, the takeaway for clinicians is to encourage their patients with multiple sclerosis (MS) to adopt healthy habits.

The drug, mastinib, reduced the chance of a confirmed disability progression by 37% in phase 2b/3 study results.

With more multiple sclerosis (MS) treatments becoming available, it is now possible to better personalize approaches, explained speakers during a session at MSVirtual 2020: 8th Joint ACTRIMS-ECTRIMS Meeting.

It is well known that women are disproportionately affected by multiple sclerosis (MS), but there remains a lack of understanding regarding gender differences in response to treatments for MS, said Riley Bove, MD, assistant professor of neurology at the UCSF Weill Institute for Neurosciences.

Do patients with multiple sclerosis who have been on disease-modifying therapies (DMTs) for decades need to keep taking them? John Corboy, MD, professor of neurology, University of Colorado Denver, School of Medicine, and co-director of the Rocky Mountain MS Center at Anschutz Medical Campus, explains what is known about this area.

Post hoc data from 2 late-stage studies about siponimod, sold as Mayzent by Novartis, illustrated improved cognitive processing speed and delayed time to disability in multiple sclerosis.